JMPWA
NBRV

JP Morgan Private Wealth Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,177
Closed -$12K – 2072
2022
Q1 		$12K Buy
1,177
+400
+51% +$4.86K ﹤0.01% 1985
2021
Q4 		$12K Buy
+777
New +$18.4K ﹤0.01% 1978

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

JP Morgan Private Wealth Advisors's NBRV Position: Q2 2022 in Review

JP Morgan Private Wealth Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2022, closing a stake of 1,177 shares — an estimated $12K sold.

JP Morgan Private Wealth Advisors first reported a position in NBRV in Q4 2021 and held it in 2 quarters. The position peaked at $12K in Q1 2022. 25 funds tracked by Wall St. Rank hold NBRV as of Q2 2022.

  • JP Morgan Private Wealth Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2022 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 1,177 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2022, an estimated $12K.
  • JP Morgan Private Wealth Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2021 and held it in 2 quarters.
  • JP Morgan Private Wealth Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $12K in Q1 2022.
  • 25 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2022.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.